Novonesis (Novozymes) B (NVZMF)
OTC
69.70
0.00 (0.00%)
Closed
Aug 21, 2026
Day's Range
69.7069.70
52 wk Range
52.1069.70
Financial Statements - NVZMF - Novonesis (Novozymes) B
Revenue
4.15B▼ 8.1%
Net Income
583.60M▲ 61.7%Net Margin 14.0%
EBITDA
1.44B▲ 1.3%
Free Cash Flow
750.70M▼ 3.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 4.15B | 4.52B | 2.40B | 17.55B | 14.95B | 14.01B |
| Cost of Goods | 1.91B | 2.38B | 1.09B | 7.97B | 6.32B | 6.15B |
| Gross Profit | 2.24B | 2.13B | 1.30B | 9.57B | 8.62B | 7.85B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 882.60M | 777.99M | 610.90M | 4.42B | 3.88B | 3.61B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 743.40M | 492.41M | 524.70M | 4.55B | 3.92B | 3.52B |
| Income Tax | 159.80M | 131.39M | 116.80M | 870M | 779M | 695M |
| Net Income | 583.60M | 361.01M | 407.90M | 3.68B | 3.14B | 2.82B |
| EPS Basic | 1.25 | 0.67 | 1.47 | 13.29 | 11.32 | 10.07 |
| EPS Diluted | 1.25 | 0.67 | 1.46 | 13.19 | 11.23 | 10.02 |
| Basic Shares Outstanding | 465.92M | 540.25M | 1.83B | 1.96B | 2.01B | 2.02B |
| Diluted Shares Outstanding | 465.92M | 540.25M | 1.83B | 1.96B | 2.01B | 2.02B |
| Ebit | 811.70M | 582.61M | 610.90M | 4.65B | 4.02B | 3.58B |
| Ebitda | 1.44B | 1.42B | 688.20M | 5.78B | 5.15B | 4.80B |
| Net Income Continuous Operations | 583.60M | 361.01M | 407.90M | 3.68B | 3.14B | 2.82B |
| Minority Interests | 0 | 0 | -2M | -10M | 1M | -1M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
